Fate’s Board of Directors has founded and led the evolution of several of the most successful companies in the biotechnology space. The group has deep expertise in science, technology, drug development, finance, and strategy – all the tools necessary to help Fate emerge as an industry leader in the development and commercialization of programmed cellular immunotherapies.
Dr. Rastetter has served as Chairman of the Board and a director since November 2011. From February 2012 to October 2012, he also served as our interim Chief Executive Officer. He is a Co-Founder of Receptos, Inc., a biopharmaceutical company that is a wholly-owned subsidiary of Celgene Corporation, where he served as a director and Chairman of the Board from 2009 to 2015, and was Acting Chief Executive Officer from May 2009 to November 2010. Dr. Rastetter also served as the Chairman of Illumina, Inc. from 2005 to 2016, and as a director of Illumina, Inc. from 1998 to 2016. Dr. Rastetter currently serves as the Chairman of Neurocrine Biosciences, Inc., as the lead outside director of Cerulean Pharma Inc., and as a director of Regulus Therapeutics, Inc. and Grail, Inc., a majority owned subsidiary of Illumina. He also serves as a strategic advisor to Leerink Partners, a healthcare focused investment bank, and as an advisor to Illumina Ventures, a genomics focused venture firm. Dr. Rastetter served as a Partner at the venture capital firm of Venrock from 2006 to February 2013. Prior to that, Dr. Rastetter was Executive Chairman of Biogen Idec, from the merger of the two companies (Biogen and Idec Pharmaceuticals) in 2003 through the end of 2005. He joined Idec Pharmaceuticals at its founding in 1986 and served as Chairman and Chief Executive Officer. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and also served in a scientific capacity at Genentech. Dr. Rastetter held various faculty positions at the Massachusetts Institute of Technology and Harvard University and was an Alfred P. Sloan Fellow. Dr. Rastetter holds a Ph.D. and M.A. in chemistry from Harvard University and an S.B. in chemistry from the Massachusetts Institute of Technology.
Dr. Mendlein is Executive Chairman and CEO of aTyr Pharma. He previously served as CEO of Adnexus Therapeutics, which was purchased by Bristol-Myers Squibb (BMY) after the award-winning partnership between Adnexus and BMY. He also served as Chairman and CEO at Affinium Pharmaceuticals, Inc., and a director, General Counsel and Chief Knowledge Officer, at Aurora Biosciences Corporation (now Vertex Pharmaceuticals, VRTX). He is currently an advisory board member of Genesys Capital, a venture capital firm in Canada, a founder and board member of Homes for Sudan, a non-profit in Boston, and a scientific advisory board member for Ocean Discovery Institute, a non-profit in San Diego.
Mr. Coughlin is currently a Vice President at Neurocrine Biosciences having served as their Chief Financial Officer from September 2006 to February 2017. Prior to Neurocrine, he served as Vice President, Financial Services with Catholic Health Initiatives, a nationwide integrated healthcare delivery system. From 1989 to 1999, Tim served as a Senior Manager in the Health Sciences practice of Ernst & Young LLP and its predecessors. Mr. Coughlin also currently serves on the Board of Directors of Retrophin. Tim holds a Master’s degree in international business from San Diego State University and a B.B.A. in accounting from Temple University.
Mr. Enyedy is President and Chief Executive Officer of ImmunoGen. He joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading Business Development, Corporate Planning and Program Management, and Strategy functions. He joined Shire in August 2013 as Head of the Internal Medicine Business Unit and has also served as Interim General Counsel and was a member of Shire’s Executive Committee. Prior to Shire, from September 2011 to July 2013, he served as Chief Executive Officer and a Director of Proteostasis Therapeutics. Prior to Proteostasis, Mark served 15 years with Genzyme Corporation, most recently as President of the Transplant, Oncology and Multiple Sclerosis divisions. As a member of Genzyme’s senior management team, he provided operational oversight and global P&L management, strategic and portfolio planning, and leadership development for these divisions. Before joining Genzyme, Mark was an associate in the business law department at Palmer & Dodge. Mark received his J.D. from Harvard Law School and his B.S. from Northeastern University. He serves on the Board of Keryx Biopharmaceuticals.
Dr. Epstein is a strategic consultant to life sciences companies and epidemiologist with extensive expertise in pharmacoeconomics and health outcomes research, having held various positions in academia and public health before joining the private sector. From 2010 to 2012, Dr. Epstein served as president of the Medco-UBC Division and as Chief Research and Development officer of Medco Health Solutions, Inc., a managed healthcare company. In these roles, Dr. Epstein was responsible for all of Medco’s clinical research initiatives, including the Medco Research Consortium (“Medco”) and United BioSource Corporation. Dr. Epstein served as Medco’s Chief Medical Officer from 1997 to 2010, leading formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life, and was also elected to the AHRQ CERT (Centers for Education and Research on Therapeutics) Committee. In addition to Fate Therapeutics, Dr. Epstein serves on the Board of Directors of Illumina, Inc., AVEO Pharmaceuticals, Inc. and Proteus Digital Health, Inc.
Dr. Nashat is a Managing General Partner at Polaris Venture Partners. His current or past directorships include Adnexus Therapeutics, Andora (where he is the founding President), Athenix Corporation, aTyr Pharmaceuticals, Avila Therapeutics, Hydra Biosciences, Pervasis Therapeutics (where he was the founding President), Promedior Pharmaceuticals, Receptos and WaveRx.
Mr. Wolchko is the President & Chief Executive Officer at Fate Therapeutics and is responsible for the company’s finance, administration and operations. Mr. Wolchko began his career as an investment banker with Morgan Stanley & Co., where he served for six years in the firm’s New York City and Menlo Park, California offices. As a member of Morgan Stanley’s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and M&A transactions. Prior to joining Fate Therapeutics, Mr. Wolchko served as the Chief Financial Officer of Bocada, Inc., where he oversaw all corporate service-related operations, and previously led Corporate Development at drugstore.com, where he was responsible for sourcing, evaluating and executing financial and business development opportunities. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont.